EE209 Can the German Efficiency Frontier Approach Support Decision-Making Processes for Pricing New Medicines? An Application to Second-Line Interventions of Transplant-Ineligible Diffuse Large B-Cell Lymphoma
For patients with diffuse large B-cell lymphoma (DLBCL), treatment options (interventions) are limited if their disease relapses or is refractory (r/r) to first-line therapy and they are ineligible for stem cell transplantation. Innovative interventions have been recently approved by the European Medicine Agency (tafasitamab-lenalidomide, Tafa-L; polatuzumab-bendamustine-rituximab, Pola-BR) for second-line (2L) treatment addressing this unmet medical need. Further interventions, e.g., CAR-T-cell therapies, are expected to be introduced for the 2L soon, albeit at rising treatment costs.
Source: Value in Health - Category: International Medicine & Public Health Authors: M.S. Kurte, A.C. Siefen, F. Jakobs, B. von Tresckow, H.C. Reinhardt, F. Kron Source Type: research
More News: Germany Health | International Medicine & Public Health | Lymphoma | Revlimid | Rituxan | Stem Cell Therapy | Stem Cells | Transplants | Treanda